Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;16(3):551-558.
doi: 10.1007/s11739-021-02639-6. Epub 2021 Feb 28.

Recurrent pericarditis: an update on diagnosis and management

Alessandro Andreis  1 , Massimo Imazio  2 , Matteo Casula  1 , Stefano Avondo  1 , Antonio Brucato  3
Affiliations
Review

Recurrent pericarditis: an update on diagnosis and management

Alessandro Andreis et al. Intern Emerg Med. 2021 Apr.

Abstract

Recurrent pericarditis is a true challenge for clinicians, especially when the patient becomes unresponsive or not tolerant to conventional treatments. An accurate diagnosis of recurrent pericarditis, possibly supported by advanced imaging tools, is critical to provide timely and appropriate treatment of symptoms and prevention of further episodes. The incessant research on the inflammatory pathways underlying cardiovascular diseases, led recently to the assessment of anti interleukin-1 agents in the setting of recurrent pericarditis. This review will focus on the diagnostic assessment of recurrent pericarditis, along with the most modern therapeutic advances in this field. Bibliographic databases were searched (MEDLINE/PubMed, BioMed Central, the Cochrane Collaboration Database of Randomized Trials, Scopus, ClinicalTrials.gov, EMBASE, Google Scholar) using the terms "recurrent pericarditis" AND "diagnosis" OR "treatment" OR "IL-1" OR "inflammation".

PubMed Disclaimer

Conflict of interest statement

MI, AB Advisory Board for KINIKSA and SOBI, others: none.

Figures

Fig. 1
Fig. 1
Early diagnostic management
Fig. 2
Fig. 2
Complications
Fig. 3
Fig. 3
Therapeutic management of patients with recurrent pericarditis
See this image and copyright information in PMC

Comment in

  • The tale of refractory recurrent pericarditis.
    Lazaros G, Antonopoulos A, Lazarou E, Vlachopoulos C, Tsioufis K. Lazaros G, et al. Intern Emerg Med. 2021 Apr;16(3):537-539. doi: 10.1007/s11739-021-02676-1. Epub 2021 Mar 18. Intern Emerg Med. 2021. PMID: 33735418 No abstract available.

References

    1. Spodick DH. Acute pericarditis: current concepts and practice. JAMA. 2003;289:1150–1153. doi: 10.1001/jama.289.9.1150. - DOI - PubMed
    1. Imazio M, Bobbio M, Cecchi E, Demarie D, Pomari F, Moratti M, Ghisio A, Belli R, Trinchero R. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med. 2005;165:1987–1991. doi: 10.1001/archinte.165.17.1987. - DOI - PubMed
    1. Imazio M, Brucato A, Cemin R, Ferrua S, Belli R, Maestroni S, Trinchero R, Spodick DH, Adler Y, CORP (COlchicine for Recurrent Pericarditis) Investigators Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155:409–414. doi: 10.7326/0003-4819-155-7-201110040-00359. - DOI - PubMed
    1. Imazio M, Belli R, Brucato A, Cemin R, Ferrua S, Beqaraj F, Demarie D, Ferro S, Forno D, Maestroni S, Cumetti D, Varbella F, Trinchero R, Spodick DH, Adler Y. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383:2232–2237. doi: 10.1016/S0140-6736(13)62709-9. - DOI - PubMed
    1. Soler-Soler J, Sagristà-Sauleda J, Permanyer-Miralda G. Relapsing pericarditis. Heart. 2004;90:1364–1368. doi: 10.1136/hrt.2003.026120. - DOI - PMC - PubMed